Some of the ADAMs, such as ADAM9, ADAM10, ADAM12, ADAM15, and ADAM17, are frequently upregulated in tumor tissues as well as cancer cell lines, and their expression often correlates with adverse patient survival and/or treatment response [11–17]. This evidence concerns the gene ADAM12 and neoplasm.